Finance Watch: Theravance Eliminates Debt In $1.1bn Trelegy Royalty Sell-Off
Also, Ultragenyx Leverages Crysvita Royalties In $500m Deal
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
